Can You Take Zepbound While Pregnant? Tirzepatide-Specific Considerations and Pre-Conception Planning

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Zepbound is not recommended in pregnancy. The FDA label directs discontinuation when pregnancy is recognized.
• Animal reproductive toxicity in rats and rabbits showed decreased fetal weights and structural abnormalities at clinically relevant exposures.
• Eli Lilly recommends pre-pregnancy discontinuation at least 1 month before planned conception, reflecting the 5-day half-life of tirzepatide.
• Zepbound carries an explicit oral contraceptive interaction warning; non-oral methods or a barrier method for 4 weeks after starting and after each dose escalation is recommended.
• Inadvertent exposure prompts standard OB-GYN evaluation, possible maternal-fetal medicine consultation, and consideration of pregnancy registry enrollment.

Direct answer

Zepbound is not recommended during pregnancy. The FDA label directs discontinuation when pregnancy is recognized, based on animal reproductive toxicity and limited human data. Lilly recommends discontinuation at least 1 month before planned conception. If you are pregnant, planning pregnancy, or breastfeeding, do not start, continue, or stop GLP-1 or GLP-1/GIP medications without OB-GYN sign-off.

Table of contents

1. What the Zepbound label says about pregnancy
2. The tirzepatide animal data, in plain English
3. Pharmacokinetics: half-life and washout
4. The oral contraceptive interaction warning
5. What this means for contraception planning
6. Pre-pregnancy discontinuation timing
7. If you become pregnant on Zepbound
8. Differences from semaglutide products
9. Postpartum and breastfeeding
10. The contrary view: dual incretins and human data
11. FAQ
12. Sources

What the Zepbound label says about pregnancy

The Zepbound prescribing information addresses pregnancy in Section 8.1. The label states there are limited data on the use of tirzepatide in pregnant women and that based on animal reproduction studies, there may be potential risk to the fetus from exposure during pregnancy. The instruction to clinicians is to discontinue Zepbound when pregnancy is recognized. The label also notes that because of the potential for serious adverse reactions, including possible teratogenicity, women of reproductive potential should be counseled about contraception.

Like Wegovy, Zepbound is approved for chronic weight management. The pregnancy framing reflects the absence of any obstetric scenario in which the underlying indication justifies continued use.

The tirzepatide animal data, in plain English

Species	Findings	Exposure context
Rat	Decreased fetal body weights, increased skeletal variations and structural abnormalities	At exposures comparable to or below the maximum recommended human dose
Rabbit	Decreased fetal body weights and structural abnormalities	At clinically relevant exposures

Animal data are not human evidence. They are signals that warrant caution while human data accumulate. The signals in tirzepatide animal studies appeared at exposures relevant to therapeutic use, which is why the label uses "discontinue" language rather than risk-benefit framing.

Pharmacokinetics: half-life and washout

Tirzepatide has a half-life of approximately 5 days. Practical implications:

• Five half-lives, or about 25 days, gives near-complete clearance.
• The manufacturer recommends discontinuation at least 1 month before planned pregnancy, which builds in additional buffer beyond pure clearance.
• Tirzepatide clears faster than semaglutide (which has a 1-week half-life and a 2-month washout recommendation).

The faster clearance does not change the basic pre-pregnancy planning principle. Inadvertent exposure during weeks 3 to 8 (organogenesis) is the most concerning window, and patients often do not recognize pregnancy until weeks 4 to 6. Pre-conception discontinuation is the only way to ensure zero first-trimester exposure.

The oral contraceptive interaction warning

Tirzepatide delays gastric emptying. For some patients, this delay is sufficient to reduce oral contraceptive absorption to a clinically meaningful degree. The Zepbound label includes a specific warning: tirzepatide may reduce the effectiveness of oral hormonal contraceptives.

Lilly's recommendation: patients using oral hormonal contraceptives should switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation of Zepbound and for 4 weeks after each dose escalation.

This is a stronger recommendation than for semaglutide, where pharmacokinetic studies did not identify a clinically meaningful oral contraceptive interaction. The difference is part of why contraceptive counseling at the start of Zepbound treatment matters.

What this means for contraception planning

Effective contraception during Zepbound treatment is layered:

• Long-acting reversible methods (IUDs, implants) are unaffected by the gastric-emptying interaction and have the lowest typical-use failure rates.
• Depot injectable methods are unaffected by oral absorption considerations.
• Oral contraceptive users should add a barrier method for 4 weeks after starting and after each dose escalation.
• Patients with PCOS or anovulatory baselines should be aware that weight loss can restore ovulation; do not rely on infrequent baseline cycles as contraception.

Pre-pregnancy discontinuation timing

Manufacturer guidance: stop Zepbound at least 1 month before planned pregnancy. The pharmacokinetic basis is the 5-day half-life and 25-day expected clearance.

Some clinicians use a more conservative 2-month window, mirroring the semaglutide recommendation, as additional buffer. The 1-month window is the formal label guidance.

Pre-pregnancy discontinuation should be planned in coordination with the prescriber. The discussion should cover alternative weight management strategies if applicable, pre-pregnancy weight goals, prenatal vitamin initiation, and contraception during the conception-planning window.

If you become pregnant on Zepbound

1. Stop the medication. Do not take additional doses.
2. Contact your prescriber and book an OB-GYN intake visit promptly.
3. Begin a prenatal vitamin with at least 400 mcg folic acid.
4. Plan for dating ultrasound and standard pregnancy intake labs.
5. Consider a maternal-fetal medicine consultation for exposure counseling.
6. Plan a detailed anatomy ultrasound at 18 to 22 weeks.
7. Consider enrolling in the Lilly tirzepatide pregnancy exposure registry.

Most patients with inadvertent first-trimester exposure go on to have uneventful pregnancies. The available data are limited, so counseling should acknowledge uncertainty without overstatement in either direction.

Differences from semaglutide products

Tirzepatide and semaglutide are different drugs with different pharmacology. Specific differences relevant to pregnancy:

• Half-life. Tirzepatide 5 days; semaglutide 1 week. Tirzepatide clears faster.
• Mechanism. Tirzepatide is a dual GLP-1 and GIP receptor agonist; semaglutide is a GLP-1 receptor agonist alone.
• Contraceptive interaction. Tirzepatide has explicit oral contraceptive precaution; semaglutide does not at the same level.
• Washout recommendation. Tirzepatide 1 month pre-conception; semaglutide 2 months pre-conception.

The general pregnancy framing (animal toxicity at clinically relevant exposures, limited human data, discontinuation directive) is similar across both classes.

Postpartum and breastfeeding

The LactMed entry for tirzepatide aligns with the semaglutide guidance: avoid use during breastfeeding until more data are available. The molecular size (about 4.8 kDa) suggests low milk transfer on theoretical grounds, but measurement data are limited.

Patients planning to breastfeed exclusively typically defer restart until weaning or transition. Postpartum metabolic considerations (weight retention, glycemic patterns) are part of the broader postpartum plan.

The contrary view: dual incretins and human data

Some clinicians point out that the dual incretin mechanism (GLP-1 plus GIP) is newer and has even less human pregnancy exposure data than semaglutide. This argues for more, not less, caution in pre-conception planning.

Other clinicians note that the animal data, while concerning, did not show novel mechanisms that would predict harm beyond what is known for the GLP-1 class. Until human registry data accumulate, the precautionary stance is appropriate.

Neither perspective changes the practical guidance: do not use during pregnancy, plan a pre-conception washout, and consult OB-GYN for inadvertent exposure.

What to verify before using this answer

The useful next step for Can You Take Zepbound While Pregnant? Tirzepatide-Specific Considerations and Pre-Conception Planning is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this women's health page, the most relevant search terms are can, you, take, zepbound, while, pregnant. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Can you take Zepbound while pregnant? No. Discontinue when pregnancy is recognized.

How long before pregnancy should I stop Zepbound? At least 1 month per manufacturer guidance.

What did the tirzepatide animal studies show? Decreased fetal weights, structural abnormalities in rats and rabbits at clinically relevant exposures.

Does Zepbound affect oral contraceptives? Yes. Use a non-oral method or add a barrier for 4 weeks after start and after each dose escalation.

What is the difference between Zepbound and Mounjaro for pregnancy? Same drug, different indication. Pregnancy precautions are the same.

What if I become pregnant on Zepbound? Stop, call your prescriber and OB-GYN, begin prenatal vitamins, plan obstetric care.

Are the pregnancy concerns the same as for Ozempic? Similar in structure; specific differences in half-life, contraceptive interaction, and washout recommendation.

Does Zepbound cause miscarriage? Animal embryofetal toxicity occurred at relevant exposures. Human miscarriage risk data are limited.

Can I use Zepbound for gestational diabetes? No. Insulin is standard.

Is breastfeeding allowed on Zepbound? LactMed recommends against until more data are available.

Related guides

• Can You Take Mounjaro While Pregnant? The Tirzepatide Diabetes Indication and Pregnancy Pathway
• Can You Take Ozempic While Pregnant? What the FDA Label, Animal Studies, and ACOG Actually Say
• Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation
• Can You Take Ozempic While Breastfeeding? The LactMed Position, Manufacturer Guidance, and What Clinicians Actually Do
• Can You Take Peptides While Breastfeeding?

Sources

1. FDA. Zepbound (tirzepatide) injection prescribing information. Warnings and Precautions, Use in Specific Populations.
2. FDA. Mounjaro (tirzepatide) injection prescribing information.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
5. American College of Obstetricians and Gynecologists. Practice Bulletin 230: Obesity in Pregnancy. 2021.
6. Eli Lilly. Tirzepatide Pregnancy Exposure Registry. Manufacturer pharmacovigilance.
7. National Library of Medicine. LactMed. Tirzepatide entry.
8. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. JCEM. 2015 with updates through 2024.
9. European Medicines Agency. Mounjaro Summary of Product Characteristics. Section 4.6.
10. Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. 2009.
11. Society for Maternal-Fetal Medicine. Consult Series on Pregnancy Care for Patients with Obesity.
12. ACOG Committee Opinion 731: Obesity in Pregnancy. 2018, reaffirmed.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not provide direct medical care. Pregnancy decisions involving GLP-1 or GLP-1/GIP medications belong to you and your OB-GYN.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed 503A pharmacy in response to an individual prescription. Pregnancy precautions described for FDA-approved tirzepatide apply with at least equal weight to compounded versions.

Results Disclaimer. This article describes general clinical context. Individual pregnancy outcomes depend on many factors beyond medication history.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.